Development and Validation of Analytical Method for Simultaneous Estimation of Formoterol Fumarate Dihydrate and Fluticasone Propionate from Bulk and Dry Powder Inhaler Formulation by Godge, Rahul K et al.
Godge et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):212-222 
ISSN: 2250-1177                                                                                  [212]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.06.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Development and Validation of Analytical Method for Simultaneous Estimation of 
Formoterol Fumarate Dihydrate and Fluticasone Propionate from Bulk and Dry 
Powder Inhaler Formulation 
Prof. Godge Rahul K*, Miss. Satpute Soniya S., Prof. Sagar Magar M. 
Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Loni tal. Rahata dist. Ahemadnagar, India 
 
ABSTRACT 
A method was developed and validated for analysis of Formoterol Fumarate and Fluticasone Propionate in dry powder inhaler for mulations. 
Separation was achieved on a HiQ Sil C18HS, 250×4.6 mm, 5 µm column using a mobile phase consisting of Acetonitrile: 0.01 M Ammonium 
Dihydrogen Phosphate solution (80:20 %v/v) at a flow rate of 1ml/min PDA detection at 215.0 nm. This method is validated according to ICH 
guidelines, which include linearity, precision, accuracy, specificity, robustness. The result obtained were within the acceptance criteria as per 
ICH guidelines.  
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INTRODUCTION 
Ultraviolet-Visible Absorption Spectroscopy:  
This deals with the absorption of electromagnetic radiation 
in the wavelength region of 160 to 780 nm. UV absorption 
spectroscopy deals with absorption of light by a sample in 
the Ultra Violet (UV) region (190 - 380 nm), while Visible 
region absorption spectroscopy (colorimetric) deals with 
absorption of light by a sample in the Visible region (380 - 
780nm). Absorption of UV – Visible light causes promotion 
of a valence electron from bonding to antibonding orbitals. 
There are 4 types of transitions observed in UV visible 
spectroscopy,   *,   *, n  *, and n  *. It is not 
always necessary that the excitation of the electron take 
place from bonding orbital to anti-bonding orbital when the 
compound is exposed to UV visible light. The relation 
between the excitation coefficient and transition probability 
is given as;   
Emax = 0.87  1020 p  a 
Where, 
Emax = excitation coefficient. 
p      = transition probability with values from 0 to 1. 
a      = target area of the absorbing system (Chromophore). 
High Performance Liquid Chromatography 
The Principle of Chromatographic Separation: 
By classical definition, chromatography is a separation 
process that is achieved by distributing the substances to be 
separated between a moving phase and a stationary phase. 
Those substances distributed preferentially in the moving 
phase pass through the chromatographic system faster than 
those that are distributed preferentially in the stationary 
phase. As a consequence the substances are eluted from the 
column in reverse order of their distribution coefficient with 
respect to the stationary phase. 
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Instrumentation: 
 
Figure 1: HPLC Instrumentation 
MATERIAL AND METHODS 
Formoterol fumarate dihydrate: Active pharmaceutical 
ingredient (API) was supplied by prerana enterprises 
(ahmednagar). 
Fluticasone propionate: Active pharmaceutical ingredient 
(API) was supplied by prerana enterprises (ahmednagar) 
All chemicals used throughout the work were of analytical 
grade and the solvents were of HPLC grade purchased from 
Merck, Mumbai. 
 
Reagents and chemicals 
Sr. No. Name Specification Manufacturer/Supplier 
1 Acetonitrile HPLC grade Merck 
2 Methanol HPLC grade Merck 
3 Orthophosphoric acid A.R Merck 
4 Ammonium dihydrogen phosphate A.R Merck 
5 Potassium dihydrogen phosphate A.R Merck 
6 Sodium dihydrogen phosphate A.R Merck 
7 Water HPLC grade Merck 
 
Apparatus/Instruments Used:  
Apparatus/Instruments  
Sr. No Name Model Manufacturer/Supplier 
1 Weighing balance  AUX 220 Shimadzu  
2 Digital pH meter  Eq610 EQUIP-TRONICS  
3 Sonicator Fast Clean  Ultrasonic Cleaner 
4 HPLC 2075 JASCO 
5 Column HiQ Sil C18HS, 250×4.6mm, 5 µm KYA TECH 
 
Experimental 
Development and Optimization of HPLC Method for Formoterol Fumarate Dihydrate and Fluticasone Propionate 
Method I -   Simultaneous Equation Method 
 Selection of solvent: Methanol is selected as a solvent 
 Selection of analytical wavelength:  
 
Figure 2: UV spectra of FFD in methanol 
FFD - 215nm 
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Figure 3: UV spectra of FP in methanol 
  
Figure 4: Overlain UV spectra of FFD & FP in methanol 
 Selection of linearity range: 
 
 
Figure 5: Standard calibration curve for FFD at 215 nm 
 
Figure 6: Standard calibration curve for FP at 236nm 
 Determination of absorptivity at analytical wavelengths: 
 Standard absorptivity values of FFD and FP 
Drug λ1=215 λ2=236 
Formoterol Fumarate Dihydrate ax1=  9.7137 ax2 = 2.961 
Fluticasone Propionate ay1 =  1.5829 ay2 =  4.0373 
 
y = 0.1236x - 0.0543 
R² = 0.9965 
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 Analysis of Marketed formulation: 
Table 1: Analysis of marketed formulation 
Sr. 
no. 
Capsule 
components 
Label Claim (mcg) % of Amount 
found*  
S.D* %R.S.D. *  
1 FFD 6 99.60 1.5857 1.5919 
2 FP 100 101.18 1.2494 1.2348 
* denotes average of three determinations. 
Validation of simultaneous equation method: 
   a. Precision:  
Table 2: Precision Study data 
 Intraday study  Inter day study 
Drug % of Amount 
found*  
S.D.* % RSD* Drug % of Amount 
found*  
S.D.* % RSD* 
 FFD 99.87 1.6310 1.63300  FFD 99.97 1.65210 1.65300 
  FP 100.12 1.63100 1.62901   FP 100.22 1.63600 1.63501 
 
b. Accuracy: 
Table 3: Recovery study data 
Level of recovery Drug By Simultaneous Equation   
% Recovery * S.D.* 
80 % FFD 99.63 0.5431 
FP 100.36 0.59002 
100 % FFD 99.67 0.613807 
FP 100.32 0.613808 
120 % FFD 100.70 1.2997 
FP 99.29 1.2998 
 
c. Ruggedness:  
Table 4: Ruggedness Data (Analyst to analyst) 
Drug 
           Concentration 
(µg/ml) 
Analyst I Analyst II 
% of Amount 
found* 
%RSD* 
% of Amount 
found* 
%RSD*  
FFD 6 99.60 1.5919 100.12 1.62901 
FP 100 101.18 1.2348 99.87 1.63300 
 
d. Limit of detection (LOD) and Limit of quantitation (LOQ): 
 
 
 
 
Method II -   Q Analysis or Absorbance Ratio Method 
 Preparation of Standard Stock Solutions: 
 Selection of linearity range: 
Linearity range was found to be 2-20 for both FFD & FP.  
 
Parameter FFD        FP 
*L.O.D. (µg/ml) 1.5 2.10 
*L.O.Q. (µg/ml) 1.3 2.0 
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Procedure for analysis: 
 Analysis of formulation: 
Table 5: Analysis of marketed formulation 
Sr. no. Capsule 
components 
Label Claim 
(mcg) 
% of Amount found*  S.D* %R.S.D.* 
1 FFD 6 100.86 1.03890 1.03002 
2 FP 100 98.32 0.2869 .0291801 
 Validation of absorbance ratio method: 
      1. Precision:  
Table 6: Precision Study data 
 Intraday study  Inter day study 
Drug % of Amount 
found*  
S.D.* % RSD* Drug % of Amount 
found* 
S.D. % RSD* 
 FFD 100.05 1.7937 1.7928  FFD 100.12 1.6937 1.6928 
  FP 99.94 1.79398 1.7947   FP 99.89 1.69398 1.6947 
*Mean of six estimation 
2. Accuracy: 
Table 7: Recovery study data 
Level of recovery Drug By Absorbance ratio method 
Recovery %* S.D.* 
80 % FFD 99.63 1.2675 
FP 100.36 1.2685 
100 % FFD 100.26 0.9679 
FP 99.73 0.9689 
120 % FFD 99.74 1.6937 
FP 100.25 1.6938 
 
3. Ruggedness:  
Table 8: Ruggedness Data 
Drug 
Concentration 
(µg/ml) 
Analyst I* %RSD Analyst II * %RSD 
FFD 6 100.05 1.7928 100.12 1.6928 
FP 100 99.94 1.7947 99.89  1.6947 
*Mean of three observations 
  4. Limit of detection (LOD) and limit of quantitation (LOQ): 
Parameter FFD FP 
*L.O.D. ( µg/ml) 1.6 2.2 
*L.O.Q. ( µg/ml)  1.2 2.0 
 
Method –III    First Order Derivative Method 
 Preparation of standard stock solutions:  
 Selection of analytical wavelength ranges: 
  
Figure 7: Overlain derivative spectra of FFD and FP 
Zero Crossing Point  
of FFD at 268nm 
Zero Crossing Point  
of FP at 236nm 
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 Selection of linear concentration ranges: 
 
Figure 8: Calibration curves for FP  
 
Figure 9: Calibration curves for FFD  
Table 9: Parameters for calibration curves: 
Parameters FFD FP 
 At 236 nm At 268 nm 
Linearity range (μg/ml) 2-20 2-20 
*Slope  0.00234 0.00078 
*Intercept  0.000 0.000 
*Regression coefficient (r2)  0.999 0.990 
 
 Determination of coefficient of absorptivities (dA/dλ) at analytical wavelength: 
The standard Absorptivity values of drugs at the selected wavelengths are: 
Table 10: Standard absorptivity values of FFD and FP 
Drug λ1=236 λ2=268 
Formoterol Fumarate Dihydrate ax1=  2.2264 X 10-2  ax2 = 9.50734X 10-5  
Fluticasone Propionate ay1 =  -3.5103 X 10-4 ay2 =  -6.88466X 10-3  
 
 Analysis of marketed formulation:  
Table 11: Results of analysis of marketed formulation 
Sr. 
no. 
Capsule 
components 
Label Claim (mcg) % amount 
found* 
S.D* %R.S.D.* 
1 FFD 6 100.25 1.462 1.473 
2 FP 100 98.40 1.356 1.383 
* Average of six determinations 
 Method validation: 
6.1C.6.1. Precision:  
6.1C.6.1.1. Repeatability:  
Studies were carried out as described in Method I. The standard deviation (S.D.), % relative standard deviation (%R.S.D.) and  
standard error (S.E.) were calculated.  
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6.1C.6.1.2. Intermediate precision (Intra-day and inter-day precision):  
The Intra and inter-day precision was determined as mentioned in method I. The S.D., % R.S.D. and S.E. were calculated and are 
shown in Table No.12. 
Table 12: Statistical evaluation for precision studies 
Precision 
   Parameter 
% Mean* S.D.* % R.S.D.* 
FFD FP FFD FP FFD FP 
Intra-day 100.28 99.41 0.6123 1.0303 0.61059 0.0555 
Inter-day 99.92 99.95 0.1199 0.0991 0.1199 1.04695 
*Average of six determinations 
6.1C.6.2. Accuracy:  
Table 13: Results of recovery studies 
Level of 
% Recovery 
%* Mean Recovery S.D.* %R.S.D.* 
FFD FP FFD FP FFD FP 
80 100.08 9989 0.1916 0.2929 0.1915 0.2936 
100 99.56 99.84 0.02524 0.05571 0.2535 0.0558 
120 100.04 101.05 0.1100 0.1438 0.1099 0.1423 
*Average of three determinations 
6.1C.6.3. Limit of Detection (LOD) and Limit of Quantitation (LOQ):  
Table 14: LOD and LOQ values 
Sr. 
No. 
Component *LOD ( µg/ml) *LOQ (µg/ml) 
1. FFD 1.2 2.0 
2. FP 1.5 2.4 
 
6.2.4. Method Development for Formoterol Fumarate Dihydrate and Fluticasone Propionate: 
 Selection of Solvent – Mobile Phase was used as diluents for dilutions.  
6.2.4.1. Preparation of stock solutions of standard:  
The standard FFD, 10 mg and FP, 100 mg were dissolved separately in diluent in separate 100 ml volumetric flasks and volume 
was made with the same solvent to give stock solutions of 100μg/ml for FFD & 1000 μg/ml for FP. 
6.2.4.2. Selection of analytical wavelength:  
6.2.4.3. Optimization of mobile phase: 
 
Figure 10: Chromatographic conditions 1 – Mobile phase - Water:ACN(30:70) 
 
Figure 11: Chromatographic conditions 2 - Mobile phase - ACN: Methanol 70:30) 
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Figure 12: Chromatographic conditions 3 - Mobile phase - ACN:Buffer(potassium dihydrogen  phosphate)  (70:30) 
Table 15: Optimized chromatographic conditions for HPLC method 
HPLC Column HiQ Sil C18HS, 250×4.6mm, 5 µm 
Column temperature Ambient temperature 
Mobile Phase Acetonitrile: 0.01 M Ammonium Dihydrogen Phosphate solution (80:20 
%v/v)  
Flow rate programming Flow rate of 1ml/min 
Detection wavelength  215.0 nm 
Injection volume 20 μl 
Run time 15 min 
 
 
Figure 13: Typical chromatogram of Combination of FFD & FP obtained in Mobile Phase - Acetonitrile: 0.01 M Ammonium 
Dihydrogen Phosphate solution 
6.2.5. Preparation of standard calibration curves of FFD and FP:   
Standard calibration data for FFD 
               
Figure 14: Standard calibration curve for FFD 
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Figure 15: Standard Calibration curve for FP 
6.2.6. Analysis of the marketed formulation:  
 Table 16: Results of analysis of capsule formulation by HPLC method 
Sr. 
No. 
Drugs Label Claim 
( mcg/cap) 
Amount Found* 
(mcg/cap) 
% of  Amount found*     
1 FFD 6 5.92 98.67 
2 FP 100 101.39 101.39 
*Average of three determinations 
 
Figure 16: HPLC chromatogram of FFD and FP in capsule formulation 
6.2.7. Method validation:  
6.2.7.1. Linearity:  
Table 17: Linear regression data for calibration curves of FFD and FP for HPLC method 
Drugs Linearity range 
(μg/ml) 
Slope  y-intercept        Regression     
    coefficient (r2) 
FFD 2.4-7.8 7074 4223   0.992 
FP 10-90 25877 5070  0.993 
 
 
Figure 17: Chromatogram of FFD & FP Linearity 
y = 25877x + 5070.3 
R² = 0.9936 
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6.2.7.2. Precision:  
Table 18: Statistical evaluation for precision studies 
Precision  
Parameter 
% Mean* S.D.* % R.S.D.* 
FFD FP FFD FP FFD FP 
Intra-day 100.21 100.71 1.5834 1.9438 1.5800 1.9401 
Inter-day 100.45 99.89 1.7762 1.5264 1.7768 1.5204 
*Average of six determinations 
6.2.7.3. Specificity: 
The chromatogram of capsule sample showed only two peaks at retention time of 4.89 ± 0.02 and 9.18 ± 0.02 min for FFD and 
FP respectively (Fig. No. 25), indicating that there is no interference of the excipients present in the capsule formulation.   
6.2.7.4. Accuracy:. 
Table 19: Results of recovery studies for HPLC method 
Level of 
% Recovery 
Amount present 
(μg/ml) 
Total amount recovered 
(μg/ml) 
% Recovery 
FFD FP FFD FP FFD FP 
 
80 
 
10.8 180 10.87 181.81 100.70 101.00 
10.8 180 10.68 176.43 98.95 98.01 
10.8  180 10.82 184.23 100.24 100.20 
 
100 
 
12 200 11.76 200.29 98.04136 100.14 
12 200 12.28 201.92 101.1963 100.96 
12  200 12.33 200.61 101.5747 100.30 
 
120 
 
13.2 220 13.30 217.33 100.81 98.78 
13.2 220 13.04 224.01 98.79 101.82 
13.2  220 13.59 223.05 100.69 101.39 
 
Table 20: Statistical validation of recovery data for HPLC method 
Level of 
% Recovery 
% Mean Recovery*  
S. D.* 
 
% R.S.D.* 
FFD FP FFD FP FFD FP 
80 99.96 100.46 1.7862 1.5464 1.7868 1.5504 
100 100.27 100.47 1.9400 0.4319 1.9347 0.4298 
120 100.10 100.66 0.8292 1.3403 0.8283 1.3314 
*Average of three determinations 
6.2.7.5. Robustness:  
Table 21: Results of robustness testing for HPLC method 
Flow Rate (ml/min) Retention time Tailing factor 
FFD FP FFD FP 
0.9 4.43 8.39 1.264 1,18 
1.0 4.78 9.22 1.26 1.19 
1.1 5.45 10.25 1.27 1.20 
pH of  Buffer      
3.4 3.98 9.08 1.31 1,20 
3.5 4.78 9.22 1.26 1.19 
 
6.2.7.6. Limit of Detection and Limit of Quantitation:  
Table 22: LOD and LOQ values for HPLC method 
Parameter FFD        FP 
*L.O.D. (mcg/ml)  0.730634  0.896917 
*L.O.Q. (mcg/ml) 2.214043  2.717931 
                                                 *Average of three determination 
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RESULTS AND DISCUSSION 
UV SPECTROPHOTOMETRIC METHODS: 
Table 23: Result & statistical validation data for marketed formulation by UV spectrophotometric methods 
Method Drug Wavelength 
nm 
Linearity 
range(μg/ml) 
r2 Mean 
%* 
S.D.* LOD 
(µg/ml) 
LOQ 
(µg/ml) 
Simultaneous 
equation 
method 
FFD 215 2-20 0.996 99.87 1.6310 1.5 1.3 
FP 236 2-20 0.991 100.12 1.63100 
2.10 
2.0 
Absorption 
ratio method 
FFD 215 2-20 0.996 100.86 1.03890 1.6 1.2 
FP 233 2-20 0.991 98.32 0.2869 2.2 2.0 
Ist order 
derivative 
FFD 236 2-20 0.999 100.25 1.462 1.2 2.0 
FP 268 2-20 0.990 98.40 1.356 1.5 2.4 
*Average of six determination 
HPLC Method:   
Table 24: Result & statistical validation data for marketed formulation by HPLC method 
Drug Wavelength 
nm 
r2 Linearity 
range 
(μg/ml) 
Mean 
%* 
S.D.* LOD 
(mcg/ml) 
LOQ 
(mcg/ml) 
FFD 215 0.992 2.4-7.8 100.21 1.5834 0.730634 2.214043 
FP 215 0.993 10-90 100.45 1.7762 0.896917 2.717931 
*Average of six determination 
SUMMARY AND CONCLUSION 
Three UV spectrophotometric methods have been developed 
for simultaneous determination of Formoterol Fumarate 
Dihydrate & Fluticasone Propionate in dry powder 
Inhalation formulation. The first method employs 
simultaneous equations (Method I) which involve 
absorbance measurement at 215nm (λ max of FFD) and 
236nm (λ max of FP). Second method involves absorbance 
ratio (Method II), absorbance measurement at 215nm (λ max 
of FFD) which takes advantage of the isobestic point at 
233nm. Third method involves first order derivative 
spectroscopy which take advantage of zero crossing point at 
236, 268nm respectively Formoterol Fumarate Dihydrate & 
Fluticasone Propionate. 
The developed HPLC method is simple, sensitive and 
reproducible for the simultaneous determination of 
Formoterol Fumarate Dihydrate & Fluticasone Propionate in 
dry powder Inhalation formulation, without any interference 
from the excipients. The HPLC method includes use of 
reverse phase HiQ Sil C18HS, 250×4.6mm, 5µm column, at 
ambient temperature using a mobile phase consisting of 
Acetonitrile: 0.01 M Ammonium Dihydrogen Phosphate 
solution (80:20 %v/v) at pH 3.5 adjusted with o-phosphoric 
acid at 1ml/min flow rate. Retention time was found to be 
4.89, 9.22 min for Formoterol Fumarate Dihydrate & 
Fluticasone Propionate, respectively. Quantization was 
achieved with UV detection at 215nm based on peak area 
with linear calibration curves at concentration range 2.4-
7.8μg/ml (r2 =0.992) for Formoterol Fumarate Dihydrate 
and 10-90μg/ml (r2 =0.993) for Fluticasone Propionate.  
The methods have been successively applied to simultaneous 
determination of Formoterol Fumarate Dihydrate & 
Fluticasone Propionate in dry powder Inhalation 
formulation.  The methods were successfully validated as per 
ICH guidelines. 
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